Scientific Focus We are a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance abuse disorders. Our discovery platform currently focuses on single molecules that function through multiple mechanisms designed to target the complexity of the CNS disease state. We believe that this approach may potentially offer new treatment options for patients, including those who are refractory to currently available treatments. Our current focus is in the therapeutic areas of rare hypersomnia disorders (conditions characterized by excessive daytime sleepiness, or EDS, such as narcolepsy) and complex neurodevelopmental disorders. Our drug development pipeline features our lead product candidate, Quilience®, for the treatment of EDS and cataplexy associated with narcolepsy, and our follow-on drug candidate Nolazol®, for the treatment of ADHD. This website uses cookies for analysis. You can find exact details in our privacy policy. No thank youOk Partnerships Contact NLS Pharmaceutics AG Alter Postplatz 2 CH-6370 Stans NW Switzerland P: +41 41 618 80 00 F: +41 41 618 80 09 contact@nls-pharma.com About NLS Science News Investors About Contact Legal Privacy Policy Terms and Conditions Cookie Policy Follow us ©2021 NLS Pharmaceutics. All rights reserved.